Genomic prediction of coronary heart disease

Genetics plays an important role in coronary heart disease (CHD) but the clinical utility of genomic risk scores (GRSs) relative to clinical risk scores, such as the Framingham Risk Score (FRS), is unclear. Our aim was to construct and externally validate a CHD GRS, in terms of lifetime CHD risk and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:European heart journal Ročník 37; číslo 43; s. 3267 - 3278
Hlavní autoři: Abraham, Gad, Havulinna, Aki S, Bhalala, Oneil G, Byars, Sean G, De Livera, Alysha M, Yetukuri, Laxman, Tikkanen, Emmi, Perola, Markus, Schunkert, Heribert, Sijbrands, Eric J, Palotie, Aarno, Samani, Nilesh J, Salomaa, Veikko, Ripatti, Samuli, Inouye, Michael
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 14.11.2016
Témata:
Coronary Disease
Female
Genomics
Heart Diseases
Humans
Male
Polymorphism, Single Nucleotide
Risk Assessment
Risk Factors
Myocardial infarction
Primary prevention
Coronary heart disease
Framingham risk score
Genomic risk score
ISSN:1522-9645
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Genetics plays an important role in coronary heart disease (CHD) but the clinical utility of genomic risk scores (GRSs) relative to clinical risk scores, such as the Framingham Risk Score (FRS), is unclear. Our aim was to construct and externally validate a CHD GRS, in terms of lifetime CHD risk and relative to traditional clinical risk scores. We generated a GRS of 49 310 SNPs based on a CARDIoGRAMplusC4D Consortium meta-analysis of CHD, then independently tested it using five prospective population cohorts (three FINRISK cohorts, combined n = 12 676, 757 incident CHD events; two Framingham Heart Study cohorts (FHS), combined n = 3406, 587 incident CHD events). The GRS was associated with incident CHD (FINRISK HR = 1.74, 95% confidence interval (CI) 1.61-1.86 per S.D. of GRS; Framingham HR = 1.28, 95% CI 1.18-1.38), and was largely unchanged by adjustment for known risk factors, including family history. Integration of the GRS with the FRS or ACC/AHA13 scores improved the 10 years risk prediction (meta-analysis C-index: +1.5-1.6%, P < 0.001), particularly for individuals ≥60 years old (meta-analysis C-index: +4.6-5.1%, P < 0.001). Importantly, the GRS captured substantially different trajectories of absolute risk, with men in the top 20% of attaining 10% cumulative CHD risk 12-18 y earlier than those in the bottom 20%. High genomic risk was partially compensated for by low systolic blood pressure, low cholesterol level, and non-smoking. A GRS based on a large number of SNPs improves CHD risk prediction and encodes different trajectories of lifetime risk not captured by traditional clinical risk scores.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1522-9645
DOI:10.1093/eurheartj/ehw450